Clinical Data UCB reports positive outcomes for bimekizumab in psoriatic arthritis PharmaTimesTrial shows first headtohead superiority in joint endpoints for an approved PsA biologicImmunology & InflammationRead full story pharminent May 19, 2026 (Last updated: May 19, 2026) PharmaTimes Trial shows first headtohead superiority in joint endpoints for an approved PsA biologic Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: European study shows inequality in access to new medicinesNext: BioMarin suffers another blow to rare disease portfolio in Phase 3 flop Related Stories Clinical Data Relay doubles the bar, outpacing Novartis with a 60% response in rare disease pharminent May 19, 2026 Clinical Data BioMarin suffers another blow to rare disease portfolio in Phase 3 flop pharminent May 19, 2026 Clinical Data Sanofi says drug for rare disease AATD tops standard care pharminent May 19, 2026
